Trial · NCT07895095
Oral Immunotherapy for Children With Peanut Allergy
NCT07895095, Not applicable, Not yet recruiting, Laura Ozer Kettner
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oral Immunotherapy for Children With Peanut Allergy. Trials, record NCT07895095. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895095
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oral Immunotherapy for Children With Peanut Allergy
- NCT number
- NCT07895095
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 56 participants, estimated
- Lead sponsor
- Laura Ozer Kettner
- Conditions
- Peanut Allergic Subjects, Peanut Allergies, Peanut Hypersensitivity, Food Allergy Peanut, Food Allergy in Children, Food Allergies
- Interventions
- Oral immunotherapy with peanut
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tolerance to peanut (4000 mg) | 1-1.5 years after enrollment | Proportion of children who tolerate a cumulative dose of 4000 mg of peanut protein at an oral food challenge |
| Secondary | Tolerance to peanut (1000 mg) | 1-1.5 years after enrollment | Proportion of children who tolerate a cumulative dose of 1000 mg of peanut protein at an oral food challenge |
| Secondary | Eliciting dose | At enrollment and 1-1.5 years after enrollment | Change in cumulative eliciting dose at an oral food challenge (mg peanut protein) |
| Secondary | Allergic reactions | 6 months, 1-1.5 years, and 2-2.5 years after enrollment | Proportion of children experiencing allergic reactions to peanut outside the oral food challenge, the number of reactions per child, and the severity of the reactions (World Allergy Organization grading system, grade 1-5; higher grades indicate more severe reactions) |
| Secondary | Use of adrenaline auto-injector | 6 months, 1-1.5 years, and 2-2.5 years after enrollment | Proportion of children for whom an adrenaline auto-injector was used due to allergic reactions to peanut outside the oral food challenge, and the number of uses per child |
| Secondary | Severity of allergic reactions at the oral food challenge according to the World Allergy Organization Grading System | 1-1.5 years after enrollment | Severity of allergic reactions to peanut at the oral food challenge, graded by the World Allergy Organization grading system (grade 1-5; higher grades indicate more severe reactions) |
| Secondary | Parental food allergy-related quality of life | At enrollment, 1-1.5 years, and 2-2.5 years after enrollment | Changes in quality of life scores measured by the Food Allergy Quality of Life - Parental Burden Questionnaire (FAQL-PB). Total scores range from 0 to 102, with higher scores indicating worse food allergy-related quality of life |
| Secondary | Parental food allergy-related anxiety | At enrollment, 1-1.5 years, and 2-2.5 years after enrollment | Changes in anxiety scores measured by the Impairment Measure for Parental Food Allergy-Associated Anxiety and Coping Tool (IMPAACT). Total scores range from 0 to 196. Subscale scores are also reported: Cognitive subscale (range 9 to 63), Behavioral subscale (range 9 to 63), Anxiety impact (range 8 to 56), and Child coping (range 2 to 14). For all scores, higher values indicate greater food allergy-related burden. |
| Secondary | Changes in specific immunoglobulin E (IgE) | At enrollment, 1-1.5 years, and 2-2.5 years after enrollment | Changes in peanut-specific IgE (kU/L) |
| Other | Characterization of allergic reactions during oral immunotherapy | During oral immunotherapy up-dosing and maintenance phase | The anticipated cause, the treatment received, the timing, and whether the reaction followed a dose increase |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895095
GET https://conductscience.org/api/trials/v1/NCT07895095/registered